ArticleAnnals of intensive care2026
Age-associated outcomes in cardiogenic shock supported with microaxial flow pumps.
Article in Annals of intensive care, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Beyond chronological age: physiological reserve and myocardial recovery potential in a european registry of microaxial flow pump in cardiogenic shock.Annals of intensive care · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Age represents a critical prognostic factor in cardiogenic shock (CS), yet older patients are underrepresented in randomized trials evaluating temporary mechanical circulatory support (tMCS). We aimed to assess the impact of age on outcomes in CS patients supported with micro-Axial Flow Pump (mAFP) across the age spectrum. Methods: We analyzed patients with CS treated with mAFP (Impella CP, 5.0 and 5.5) across 11 European centers between 2010 and 2023. Patients were stratified into quartiles by age: Q1 ≤ 52.0 years, Q2 > 52.0-60.0 years, Q3 > 60.0-69.0 years, and Q4 ≥ 69.0 years. The association between age and mortality was assessed using a Fine-Gray competing risks model and restricted cubic spline analysis. The primary endpoint was all-cause mortality at 30 days. Results: Among 1,043 patients supported with mAFP, the oldest quartile (Q4) was more frequently female, had higher comorbidity burden, and received less intensive support compared to Q1. In the Fine-Gray competing risks model, Q3 and Q4 patients had significantly higher 30-day and 1-year mortality risks (30-day: adjusted sHR 1.66 [95% CI: 1.19-2.34] and 1.87 [1.34-2.62]; 1-year: sHR 1.78 [1.31-2.41] and 2.08 [1.54-2.80]; Ptrend < 0.01 for all), with each additional year of age conferring a 3.2% increase in 30-day mortality risk (adjusted sHR 1.032 [1.017-1.047]). Major left ventricular ejection fraction (LVEF) recovery (≥10 percentage points) declined progressively with age, from 74.5% in Q1 to 41.9% in Q4 (p < 0.01), with each year associated with a 0.40 percentage-point reduction in LVEF improvement. Conclusions: In this European registry, increasing age was associated with higher mortality and lower observed myocardial recovery among patients with cardiogenic shock supported with mAFP.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.